Kiora Pharmaceuticals Management
Management criteria checks 4/4
Kiora Pharmaceuticals' CEO is Brian Strem, appointed in Jul 2021, has a tenure of 3.5 years. total yearly compensation is $802.27K, comprised of 51.9% salary and 48.1% bonuses, including company stock and options. directly owns 1.01% of the company’s shares, worth $109.48K. The average tenure of the management team and the board of directors is 3.3 years and 3.8 years respectively.
Key information
Brian Strem
Chief executive officer
US$802.3k
Total compensation
| CEO salary percentage | 51.9% |
| CEO tenure | 3.5yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem
May 21
Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement
Oct 13Kiora Pharma announces 1-for-40 reverse stock split
Sep 26Kiora Pharmaceuticals reports 1H results
Aug 12Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing
Jul 28Kiora Pharmaceuticals prices $5.2M underwritten public offering
Jul 22Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201
Jul 05EyeGate Pharmaceuticals announces $8M private placement
Jan 06EyeGate surge in premarket as it acquires Panoptes Pharma for $4M
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | n/a | n/a | US$3m |
| Mar 31 2024 | n/a | n/a | US$2m |
| Dec 31 2023 | US$802k | US$416k | -US$13m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$12m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$714k | US$400k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$17m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$15m |
| Dec 31 2021 | US$659k | US$169k | -US$14m |
Compensation vs Market: Brian's total compensation ($USD802.27K) is about average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Strem (45 yo)
3.5yrs
Tenure
US$802,274
Compensation
Dr. Brian M. Strem, Ph D., is Co-Founder and Director at Okogen, Inc. He served as Principal Financial and Accounting Officer of Kiora Pharmaceuticals, Inc. since June 16, 2022. He serves as President, Dir...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$802.27k | 1.01% $ 109.5k | |
| Chief Financial Officer | 2.3yrs | US$387.48k | 0.45% $ 49.4k | |
| Chief Development Officer | 3.3yrs | US$652.31k | 0.62% $ 67.4k | |
| Executive Vice President of CMC & Operations | no data | no data | no data |
3.3yrs
Average Tenure
45yo
Average Age
Experienced Management: KPRX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.5yrs | US$802.27k | 1.01% $ 109.5k | |
| Independent Director | less than a year | no data | 0.042% $ 4.5k | |
| Member of Scientific Advisory Board | 7.8yrs | no data | no data | |
| Independent Chairman of the Board | 16.6yrs | US$98.25k | 0.17% $ 18.2k | |
| Member of Scientific Advisory Board | 7.3yrs | no data | no data | |
| Director | 3.8yrs | US$70.12k | 0.10% $ 10.9k | |
| Member of Scientific Advisory Board | 6.9yrs | no data | no data | |
| Independent Director | 3.1yrs | US$77.62k | 0% $ 0 | |
| Non-Employee Independent Director | 2.9yrs | US$84.50k | 0.18% $ 19.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.8yrs
Average Tenure
53yo
Average Age
Experienced Board: KPRX's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 03:57 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kiora Pharmaceuticals, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Keay Nakae | Chardan Capital Markets, LLC |
| Yi Chen | H.C. Wainwright & Co. |
| Matthew Kaplan | Ladenburg Thalmann & Company |